Ginkgo Bioworks Holdings, Inc. (DNA) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.The ...

Customizable, anaerobic-enabled system aims to accelerate discovery and development of sustainable biofuels at the University of Wisconsin–Madison's GLBRCBOSTON, Jan. 23, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Ginkgo Automation will design and deploy a flexible, anaerobic-enabled laboratory automation system for the Great Lakes Bioenergy Research Center (GLBRC), a U.S. Department of Energy-funded Bio ...

Core View - Ginkgo Bioworks collaborates with Universal Cells, an Astellas company, to optimize next-generation iPSC-derived cancer cell therapies, leveraging Ginkgo's high-throughput biological approaches to address challenges in solid tumor therapy development [1] - The collaboration aims to enhance the potency and persistence of iPSC-derived immune cell therapeutics by combining Universal Cells' proprietary technologies with Ginkgo's expertise in CAR library design, screening, and immune cell engineering [2] Collaboration Details - The partnership focuses on improving the scalability and manufacturability of 'off-the-shelf' iPSC-derived cell therapies, which have the potential to transform cancer care [2] - Ginkgo's platform capabilities include CAR discovery and optimization, cell survival enhancement strategies, and gene editing tools for immune cell engineering, enabling rapid exploration and refinement of therapeutic designs [3] Ginkgo's Platform Strengths - Ginkgo employs computational tools, deep expertise in library assembly, and rigorous statistical analysis to accelerate the discovery and engineering of optimal therapeutic designs [3] - The company's high-throughput pooled and arrayed screening methods allow simultaneous testing of numerous CAR designs, aiming to improve immune cell persistence and functionality [3] Strategic Impact - The collaboration represents a significant milestone for Ginkgo as it expands its cell therapy portfolio and brings its immune cell engineering capabilities to a global pharmaceutical leader [4] - The partnership aims to optimize iPSC-derived allogeneic cell therapies, potentially improving patient outcomes and reshaping the treatment of solid tumors [4] Industry Context - Ginkgo Bioworks is a leading horizontal platform for cell programming, offering end-to-end services across diverse markets, including pharmaceuticals, food, agriculture, and industrial chemicals [5] - The company is also building next-generation biosecurity infrastructure and technologies to address global biological threats [5]

Company Presentation - Ginkgo Bioworks CEO Jason Kelly is scheduled to present at the 43rd Annual J P Morgan Healthcare Conference on January 16 2025 at 10 30 a m PT (1 30 p m ET) [1] - Further details webcast link and a replay of the presentation will be posted on the company's investor relations website [1] Company Overview - Ginkgo Bioworks is the leading horizontal platform for cell programming providing flexible end-to-end services across diverse markets including food and agriculture pharmaceuticals and industrial and specialty chemicals [2] - Ginkgo Biosecurity is building next-generation infrastructure and technologies to help global leaders predict detect and respond to biological threats [2] Contact Information - Investor contact email is provided for inquiries [3] - Media contact email is provided for inquiries [3]

Ginkgo Bioworks Holdings, Inc. (DNA) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate. ...

Ginkgo Bioworks to apply its mammalian cell engineering expertise to develop new cell-based systems for treating and monitoring endocrine disordersBOSTON, Dec. 17, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a subcontract of up to $9.4 million awarded in partnership with Carnegie Mellon University to develop bioelectronic cell-based devices aimed at diagnosing and treating hormone disorders. This initiative is ...

Ginkgo Bioworks (NYSE: DNA ) reported solid results in the third quarter, although the company's performance was weaker than the financials suggest, as Ginkgo recognized 45 million USD of non-cash revenue that has no value. Ginkgo's transition away from downstream value Richard Durant is the leader of Narweena, an asset manager focused on finding market dislocations that are the result of a poor understanding of a businesses long-term prospects. Narweena believes that excess risk adjusted returns can be ach ...

I am a market enthusiast and part-time trader. I started writing for Seeking Alpha in 2011, and it has been a tremendous opportunity and learning experience. I have been interested in the markets since elementary school, and hope to pursue a career in the investment management industry. I have been active in the markets for several years, and am primarily focused on long/short equities. I hold a Bachelor of Science Degree from Lehigh University, where I double majored in Finance and Accounting, with a minor ...

Financial Data and Key Metrics Changes - The company ended Q3 2024 with $616 million in cash and no bank debt, exceeding its cost-cutting target for 2024 [5][8] - Adjusted EBITDA improved to negative $20 million from negative $84 million in Q3 2023, attributed to cost-cutting initiatives and a noncash deferred revenue release [22][26] - Total revenue guidance for the year was updated to $215 million to $235 million, with cell engineering services revenue expected to be $165 million to $185 million [25][26] Business Line Data and Key Metrics Changes - Cell engineering revenue was $30 million, down 20% year-over-year, primarily due to a shift from small early-stage customers to large enterprise customers [11][12] - The biosecurity business generated $14 million in revenue with a gross margin of 28%, showing a decline quarter-over-quarter [17] - The company supported 136 active programs across 81 customers in cell engineering, a 17% increase year-over-year [12] Market Data and Key Metrics Changes - The company is seeing strong traction in its newly launched data points business, with recent wins from top 25 biopharma customers [7][56] - The sales pipeline for both cell engineering and data points deals is strong, indicating potential for future growth [16] Company Strategy and Development Direction - The company aims to reach adjusted EBITDA breakeven while maintaining a cash margin of safety, with significant cost reductions already achieved [5][8] - There is a strategic focus on expanding revenue in solutions while also selling tools, with a notable emphasis on partnerships with blue-chip customers [6][30] - The company is consolidating operations and reducing costs, including a 35% reduction in workforce and significant cuts in contractor and professional fees [33][34] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's ability to navigate the current biotech downturn and emphasized the importance of reaching breakeven without needing to raise additional capital [80] - The company is focused on executing within its core areas of government, pharma, and agriculture, which now account for over 70% of its business [84] - Management highlighted the potential for growth in the biosecurity sector, particularly in light of recent health concerns related to H5N1 [66][71] Other Important Information - The company recognized $45 million in noncash revenue from the termination of a customer agreement with Motif FoodWorks, which impacted revenue reporting [10][25] - Cash burn in Q3 was affected by nonrecurring items, including litigation settlements and employee severance, but is expected to decrease significantly in Q4 [23][24] Q&A Session Summary Question: Can you provide more clarity into what the Company's strategy is? - The company is expanding into tools to leverage existing assets and provide advanced bioengineering technologies, aiming for breakeven while tightening spending [78][81] Question: Have you started to notice a clear improvement in resource utilization and efficiency? - The company has shifted focus towards government and pharma, leading to efficiency gains and cost reductions while maintaining revenue targets [84][86] Question: Any signs of sequential stabilization in biopharma funding? - There are signs of life in biopharma funding, with the company seeing initial deals with major biopharma, although the overall market remains challenging [89][90] Question: How has the transition been towards a multiproduct or multiservice company? - The transition has been positive, with synergies between offerings and a focus on ensuring internal teams are aligned to deliver products effectively [95][99] Question: Can we expect one-time costs associated with restructuring to repeat? - The company expects total one-time costs related to restructuring to be in the range of $18 million to $22 million, with approximately $15 million accrued to date [104]

Ginkgo Bioworks Holdings, Inc. (DNA) came out with a quarterly loss of $1.08 per share versus the Zacks Consensus Estimate of a loss of $2.40. This compares to loss of $3.60 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 55%. A quarter ago, it was expected that this company would post a loss of $3.20 per share when it actually produced a loss of $3.20, delivering no surprise.Over the last four quarters, the company has surpas ...